Half Title Page.
1: Personal Essays.
2: Challenges in Drug Discovery at Schering–Plough Research Institute: A Personal Reflection.
3: My Perspective on Time, Managers—and Scientific Fun.
4: A Career in Medicinal Chemistry—A Journey in Drug Discovery.
5: Central Nervous System Diseases.
6: Selective Inhibitors of PDE2, PDE9, and PDE10: Modulators of Activity of the Central Nervous System.
7: Beyond Secretases: Kinase Inhibitors for the Treatment of Alzheimer’s Disease.
8: Orexin Receptor Antagonists in Development for Insomnia and CNS Disorders.
9: Cardiovascular and Metabolic Diseases.
10: Discovery and Development of Prolylcarboxypeptidase Inhibitors for Cardiometabolic Disorders.
11: Molecular Targeting of Imaging and Drug Delivery Probes in Atherosclerosis.
12: Oral GLP-1 Modulators for the Treatment of Diabetes.
13: Inflammation Pulmonary GI Diseases.
14: Recent Advances in the Discovery and Development of CCR1 Antagonists.
15: Emerging Targets for the Treatment of Idiopathic Pulmonary Fibrosis.
16: Targeting the Nuclear Hormone Receptor RORγt for the Treatment of Autoimmune and Inflammatory Disorders.
18: Recent Advances in Small-Molecule Modulation of Epigenetic Targets: Discovery and Development of Histone Methyltransferase and Bromodomain Inhibitors.
19: Inhibition of Ubiquitin Proteasome System Enzymes for Anticancer Therapy.
20: Targeting Protein–Protein Interactions to Treat Cancer—Recent Progress and Future Directions.
21: Infectious Diseases.
22: Recent Progress in the Discovery of Neuraminidase Inhibitors as Anti-Influenza Agents.
23: Novel Therapeutics in Discovery and Development for Treatment of Chronic HBV Infection.
24: Special Challenges to the Rational Design of Antibacterial Agents.
25: Topics in Biology.
26: Recent Advances in Small Molecule Target Identification Methods.
27: Neuroinflammation in Mood Disorders: Mechanisms and Drug Targets.
28: Topics in Drug Design and Discovery.
29: Inhibitors of hERG Channel Trafficking: A Cryptic Mechanism for QT Prolongation.
30: Recent Progress in Small-Molecule Agents Against Age-Related Macular Degeneration.
31: Synthetic Macrocycles in Small-Molecule Drug Discovery.
32: Glossary of Terms Used in Medicinal Chemistry Part II (IUPAC Recommendations 2013).
33: Case Histories and NCEs.
34: Case History: Xalkori™ (Crizotinib), a Potent and Selective Dual Inhibitor of Mesenchymal Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) for Cancer Treatment.
35: Case History: Vemurafenib, a Potent, Selective, and First-in-Class Inhibitor of Mutant BRAF for the Treatment of Metastatic Melanoma.
36: New Chemical Entities Entering Phase III Trials in 2012.
37: To Market, To Market—2012.
Cumulative Chapter Titles Keyword Index, Volume 1 – 48.
Cumulative NCE Introduction Index, 1983–2012.
Cumulative NCE Introduction Index, 1983–2012 (by Indication).